Rein Therapeutics Inc. carries no debt; cash flow comfortably covers obligations.

Rein Therapeutics Inc.'s free cash flow has increased -13.14% from $-22.29M last year to $-19.36M, signaling increasing performance

Rein Therapeutics Inc.'s debt to equity ratio is 0.42, which means that the company's assets are healthy financed, signaling financial stability.

Rein Therapeutics Inc. has insufficient data to evaluate this check.

Rein Therapeutics Inc. has a net cash position, so leverage is healthy.

Rein Therapeutics Inc. carries no debt; interest obligations are fully covered.

Rein Therapeutics Inc. has insufficient data to evaluate this check.

Rein Therapeutics Inc.'s short-term liabilities of $6.18M exceed its short-term assets of $4.33M, signaling financial risk

Rein Therapeutics Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Rein Therapeutics Inc.'s return on equity of -258.45%, is lower than 15.00%, indicating bad performance

Rein Therapeutics Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Rein Therapeutics Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Rein Therapeutics Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Rein Therapeutics Inc. has negative free cash flow, indicating cash burn

Rein Therapeutics Inc.'s yearly earnings has increased -20.69% since last year from $-62.88M to $-49.87M, signaling increasing performance

Rein Therapeutics Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -120.92% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Rein Therapeutics Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Rein Therapeutics Inc. had revenue growth in 5 out of 5 years, indicating consistent revenue performance

Rein Therapeutics Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Rein Therapeutics Inc. has insufficient data to evaluate this check.

Rein Therapeutics Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Rein Therapeutics Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Rein Therapeutics Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Rein Therapeutics Inc. has insufficient data to evaluate this check.

Rein Therapeutics Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Rein Therapeutics Inc. has a price-to-book ratio of 2.08x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Rein Therapeutics Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue